Targeting lipogenesis blocks adaptation to antiangiogenic therapy

Area of Science:

• Metabolic pathways and cancer therapy adaptation

Background:

• Antiangiogenic therapy is a standard cancer treatment.
• Tumor resistance and adaptation limit long-term efficacy.
• Understanding adaptive mechanisms is crucial for improving treatment strategies.

Purpose of the Study:

• To investigate the metabolic changes occurring upon withdrawal of antiangiogenic therapy.
• To identify key pathways involved in tumor adaptation and potential resistance.

Main Methods:

• Utilized metabolomic analysis to profile tumor metabolic states.
• Employed stable isotope tracing to track metabolic flux.
• Assessed changes in lipogenesis markers in response to therapy withdrawal.

Main Results:

• Withdrawal of antiangiogenic therapy induced a significant metabolic shift in tumors.
• Increased activity of de novo lipogenesis was observed.
• This metabolic adaptation appears to support tumor cell survival and proliferation.

Conclusions:

• Tumor adaptation to antiangiogenic therapy withdrawal is characterized by a metabolic switch to de novo lipogenesis.
• Targeting lipogenesis could be a potential strategy to overcome resistance after therapy cessation.